Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 2/2015

01-04-2015 | Original Article

Urinary angiotensinogen level is increased in preterm neonates

Authors: Masashi Suzue, Maki Urushihara, Ryuji Nakagawa, Takahiko Saijo, Shoji Kagami

Published in: Clinical and Experimental Nephrology | Issue 2/2015

Login to get access

Abstract

Background

All components of the renin–angiotensin system (RAS) are abundantly synthesized in the developing kidney, suggesting that the RAS plays an important role in renal development. To examine this system in human neonates, we measured urinary angiotensinogen levels in preterm and full-term neonates and examined the relationship between urinary angiotensinogen levels and gestational age.

Methods

Urine and plasma samples were collected from 20 preterm and 18 full-term neonates at birth. Angiotensinogen levels were measured using enzyme-linked immunosorbent assay.

Results

Plasma angiotensinogen concentrations were not increased in preterm neonates compared with that in full-term neonates (P = 0.7288). However, the urinary angiotensinogen-to-creatinine ratio was significantly higher in preterm neonates compared with that in full-term neonates (P = 0.0011). Importantly, the urinary angiotensinogen-to-creatinine ratio dropped significantly with increasing gestational age (P = 0.0010), whereas the plasma angiotensinogen concentration was not correlated with gestational age (P = 0.7814).

Conclusions

These results suggest that urinary angiotensinogen levels may indicate the involvement of intrarenal RAS activation in prenatal renal development.
Literature
1.
Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol. 1999;10(Suppl 12):S266–72.PubMed
2.
Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251–87.CrossRefPubMed
3.
4.
5.
Madsen K, Tinning AR, Marcussen N, Jensen BL. Postnatal development of the renal medulla; role of the renin–angiotensin system. Acta Physiol (Oxf). 2013;208:41–9.CrossRefPubMed
6.
7.
Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int Suppl. 2002;61:1635–45.CrossRef
8.
Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal renin–angiotensin system activity. Am J Nephrol. 2010;31:318–25.CrossRefPubMedCentralPubMed
9.
Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009;338:478–80.CrossRefPubMedCentralPubMed
10.
Schutz S, Le Moullec JM, Corvol P, Gasc JM. Early expression of all the components of the renin–angiotensin-system in human development. Am J Pathol. 1996;149:2067–79.PubMedCentralPubMed
11.
Gubler MC, Antignac C. renin–angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int. 2010;77:400–6.CrossRefPubMed
12.
Tufro-McReddie A, Gomez RA. Ontogeny of the renin–angiotensin system. Semin Nephrol. 1993;13:519–30.PubMed
13.
Gomez RA, Robillard JE. Developmental aspects of the renal responses to hemorrhage during converting-enzyme inhibition in fetal lambs. Circ Res. 1984;54:301–12.CrossRefPubMed
14.
Pelayo JC, Eisner GM, Jose PA. The ontogeny of the renin–angiotensin system. Clin Perinatol. 1981;8:347–59.PubMed
15.
Pryde PG, Sedman AB, Nugent CE, Barr M Jr. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993;3:1575–82.PubMed
16.
Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet. 2001;358:241–2.CrossRefPubMed
17.
Mahieu-Caputo D, Dommergues M, Delezoide AL, Lacoste M, Cai Y, Narcy F, et al. Twin-to-twin transfusion syndrome. Role of the fetal renin–angiotensin system. Am J Pathol. 2000;156:629–36.CrossRefPubMedCentralPubMed
18.
Kobori H, Urushihara M. Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflugers Arch. 2013;465:3–12.PubMedCentralPubMed
19.
Lantelme P, Rohrwasser A, Gociman B, Hillas E, Cheng T, Petty G, et al. Effects of dietary sodium and genetic background on angiotensinogen and renin in mouse. Hypertension. 2002;39:1007–14.CrossRefPubMed
20.
Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, et al. Elements of a paracrine tubular renin–angiotensin system along the entire nephron. Hypertension. 1999;34:1265–74.CrossRefPubMed
21.
Nakano D, Kobori H, Burford JL, Gevorgyan H, Seidel S, Hitomi H, et al. Multiphoton imaging of the glomerular permeability of angiotensinogen. J Am Soc Nephrol. 2012;23:1847–56.CrossRefPubMedCentralPubMed
Metadata
Title
Urinary angiotensinogen level is increased in preterm neonates
Authors
Masashi Suzue
Maki Urushihara
Ryuji Nakagawa
Takahiko Saijo
Shoji Kagami
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-0977-y

Other articles of this Issue 2/2015

Clinical and Experimental Nephrology 2/2015 Go to the issue

Original Article

Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults

Original Article

Role of the p.E66Q variant of GLA in the progression of chronic kidney disease

Original Article

Urinary neopterin: an immune activation marker in mesangial proliferative glomerulonephritis

Original Article

CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy

Original Article

Disturbed circadian rhythm of the intrarenal renin-angiotensin system: relevant to nocturnal hypertension and renal damage

Original Article

Preserved autonomic heart rate modulation in chronic renal failure patients in response to hemodialysis and orthostatism
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits